Company profile

Synthekine

Privately held: no public share price (Privately held engineered-cytokine biotech; closed a $100M Series C in Jan 2023, no IPO. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.synthekine.com/news/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics/]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
STK-012
Phase 2
IL-2 receptor subunits CD25 (IL2RA) and CD122 (IL2RB)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.